Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

105.55 -0.69 (-0.65%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

2 Growth Stocks Set to Flourishand 1 Facing Challenges

November 25, 2025

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Via StockStory

Integra LifeSciences, Evolent Health, Incyte, iRhythm, and Clover Health Stocks Trade Up, What You Need To Know

November 24, 2025

A number of stocks jumped in the afternoon session after a report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies.

Via StockStory

Topics Economy

Q3 Earnings Highs And Lows: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Immuno-Oncology Stocks

November 23, 2025

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Exact Sciences (NASDAQ:EXAS) and its peers.

Via StockStory

Topics Artificial Intelligence

November 20, 2025

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other...

Via StockStory

Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3

November 19, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Natera (NASDAQ:NTRA) and the...

Via StockStory

Topics Artificial Intelligence

Top S&P500 movers in Tuesday's pre-market session ↗

November 18, 2025

Discover the top S&P500 movers in Tuesday's pre-market session and stay informed about market dynamics.

Via Chartmill

INCYTE CORP (NASDAQ:INCY) Presents a Compelling Case for Value Investors ↗

November 18, 2025

INCYTE CORP (INCY) is a strong value investing candidate with a low P/E ratio, a healthy balance sheet, and solid profitability, suggesting it's an undervalued stock.

Via Chartmill

This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗

November 18, 2025

A healthcare hedge fund just trimmed its biggest holding—right as the company posts a clinical and financial breakout year.

Via The Motley Fool

Topics Regulatory Compliance

Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗

November 18, 2025

A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals.

Via The Motley Fool

Fear Of An AI Bubble? This Sector Is Quietly Surging While Tech Sinks ↗

November 14, 2025

While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate.

Via Benzinga

Topics Artificial Intelligence

1 Mid-Cap Stock to Consider Right Now and 2 We Turn Down

November 13, 2025

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with...

Via StockStory

Peering Into Incyte Corp's Recent Short Interest ↗

November 12, 2025

Via Benzinga

Incyte (NASDAQ:INCY) Q3 Earnings: Leading The Immuno-Oncology Pack

November 10, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at immuno-oncology stocks, starting with...

Via StockStory

Topics Artificial Intelligence

Winners And Losers Of Q3: Regeneron (NASDAQ:REGN) Vs The Rest Of The Immuno-Oncology Stocks

November 10, 2025

Looking back on immuno-oncology stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.

Via StockStory

Topics Artificial Intelligence

1 Cash-Producing Stock Worth Your Attention and 2 Facing Headwinds

November 06, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

Topics Economy Supply Chain

Incyte (INCY): Buy, Sell, or Hold Post Q3 Earnings?

November 05, 2025

The past six months have been a windfall for Incyte’s shareholders. The company’s stock price has jumped 78.7%, setting a new 52-week high of $106.50 per share. This was partly due to its solid...

Via StockStory

The 5 Most Interesting Analyst Questions From Incyte’s Q3 Earnings Call

November 04, 2025

Incyte’s third quarter saw revenue and profit surpass Wall Street’s expectations, yet the market responded negatively. Management identified robust demand for key drugs Jakafi and Opzelura, alongside...

Via StockStory

Topics Earnings

Stay informed with the top movers within the S&P500 index on Monday. ↗

November 03, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday.

Via Chartmill

Kenvue, IDEXX Laboratories, Freshpet And Other Big Stocks Moving Higher On Monday ↗

November 03, 2025

Via Benzinga

These S&P500 stocks have an unusual volume in today's session ↗

November 03, 2025

Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below.

Via Chartmill

Exploring the top movers within the S&P500 index during today's session. ↗

November 03, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Via Chartmill

INCY Q3 Deep Dive: Strong Product Momentum and Pipeline Reshaping Amid Strategic Refocus

October 29, 2025

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of...

Via StockStory

Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms ↗

October 28, 2025

Incyte Q3 revenue rose 20% to $1.37 billion, topping estimates, as Jakafi and Niktimvo fueled growth and the company raised its 2025 revenue outlook.

Via Benzinga

Topics Intellectual Property

These S&P500 stocks have an unusual volume in today's session ↗

October 28, 2025

Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below.

Via Chartmill

Why Incyte (INCY) Stock Is Trading Lower Today

October 28, 2025

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 4.2% in the morning session after the company reported underwhelming third-quarter 2025 financial results.

Via StockStory

Nasdaq 100 Hits 26,000, Gold Falls Below $4,000: What's Moving Markets Tuesday? ↗

October 28, 2025

Tech stocks hit new highs as the Nasdaq 100 rallies 0.7% midday. Investors eye a Fed rate cut, Trump-Xi meeting, and major tech earnings.

Via Benzinga

Topics Economy

Incyte (INCY) Q3 2025 Earnings Call Transcript ↗

October 28, 2025

Incyte (INCY) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views ↗

October 28, 2025

The company delivered significantly better-than-expected third-quarter sales and earnings, but shares took a premarket hit.

Via Investor's Business Daily

Topics Government

Incyte Corp (NASDAQ:INCY) Reports Strong Q3 2025 Earnings, Beating Estimates ↗

October 28, 2025

Incyte (INCY) Q3 2025 earnings beat expectations with $1.37B revenue and $2.26 EPS. Driven by Jakafi and Opzelura growth, the company also raised its full-year 2025 guidance.

Via Chartmill

Topics Earnings

Incyte (NASDAQ:INCY) Reports Strong Q3

October 28, 2025

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of $2.26 per share...

Via StockStory

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Incyte Corporation - Common Stock (NQ:INCY)

Headline News about Incyte Corporation - Common Stock

Starting at $3.75/week.

Subscribe Today